GlassScriptPhysician profile
Lisa C Edsall
NPI 1194933861
$3,718.14
in general payments reported to CMS, 2019-2025
22 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.71 · 2021: $67.98 · 2022: $451 · 2023: $659 · 2024: $1,486 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.54 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $629.55 | 2022-2025 | Adbry |
| Abbvie INC. | $563.44 | 2022-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $340.76 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $301.69 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $265.59 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $224.60 | 2021-2025 | Tremfya |
| Pfizer INC. | $187.26 | 2022-2025 | |
| Ucb, INC. | $176.77 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $150.27 | 2022-2025 | |
| Amgen INC. | $134.81 | 2021-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $130.63 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $126.23 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $103.50 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.75 | 2023-2025 | Spevigo |
| Blueprint Medicines Corporation | $68.26 | 2024 | Ayvakit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.84 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Helsinn Therapeutics (U.S.), INC. | $48.81 | 2023-2024 | Valchlor |
| Galderma Laboratories, L.P. | $39.38 | 2025 | Nemluvio |
| Organon LLC | $26.29 | 2024-2025 | Vtama |
| Lnhc, INC | $24.91 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.99 | 2020-2021 | |
| Allergan, INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Edsall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.